Literature DB >> 24513675

Intralymphatic immunotherapy and vaccination in mice.

Pål Johansen1, Thomas M Kündig.   

Abstract

Vaccines are typically injected subcutaneously or intramuscularly for stimulation of immune responses. The success of this requires efficient drainage of vaccine to lymph nodes where antigen presenting cells can interact with lymphocytes for generation of the wanted immune responses. The strength and the type of immune responses induced also depend on the density or frequency of interactions as well as the microenvironment, especially the content of cytokines. As only a minute fraction of peripherally injected vaccines reaches the lymph nodes, vaccinations of mice and humans were performed by direct injection of vaccine into inguinal lymph nodes, i.e. intralymphatic injection. In man, the procedure is guided by ultrasound. In mice, a small (5-10 mm) incision is made in the inguinal region of anesthetized animals, the lymph node is localized and immobilized with forceps, and a volume of 10-20 μl of the vaccine is injected under visual control. The incision is closed with a single stitch using surgical sutures. Mice were vaccinated with plasmid DNA, RNA, peptide, protein, particles, and bacteria as well as adjuvants, and strong improvement of immune responses against all type of vaccines was observed. The intralymphatic method of vaccination is especially appropriate in situations where conventional vaccination produces insufficient immunity or where the amount of available vaccine is limited.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24513675      PMCID: PMC4395107          DOI: 10.3791/51031

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  33 in total

1.  Intralymphatic immunization enhances DNA vaccination.

Authors:  K J Maloy; I Erdmann; V Basch; S Sierro; T A Kramps; R M Zinkernagel; S Oehen; T M Kündig
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

Review 2.  Antigen presentation to naive CD4 T cells in the lymph node.

Authors:  Andrea A Itano; Marc K Jenkins
Journal:  Nat Immunol       Date:  2003-08       Impact factor: 25.606

3.  Dendritic cells injected via different routes induce immunity in cancer patients.

Authors:  L Fong; D Brockstedt; C Benike; L Wu; E G Engleman
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

4.  Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections.

Authors:  Gabriela Senti; Reto Crameri; Daniela Kuster; Pål Johansen; Julia M Martinez-Gomez; Nicole Graf; Martin Steiner; Ludwig A Hothorn; Hans Grönlund; Christine Tivig; Anna Zaleska; Ozge Soyer; Marianne van Hage; Cezmi A Akdis; Mübeccel Akdis; Horst Rose; Thomas M Kündig
Journal:  J Allergy Clin Immunol       Date:  2012-03-30       Impact factor: 10.793

Review 5.  New routes for allergen immunotherapy.

Authors:  Pål Johansen; Seraina von Moos; Deepa Mohanan; Thomas M Kündig; Gabriela Senti
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

6.  Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors.

Authors:  Kent A Smith; Brenna L Meisenburg; Victor L Tam; Robb R Pagarigan; Raymond Wong; Diljeet K Joea; Liz Lantzy; Mayra A Carrillo; Todd M Gross; Uriel M Malyankar; Chih-Sheng Chiang; Diane M Da Silva; Thomas M Kündig; W Martin Kast; Zhiyong Qiu; Adrian Bot
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

7.  Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.

Authors:  Thomas Schwaab; Adrian Schwarzer; Benita Wolf; Todd S Crocenzi; John D Seigne; Nancy A Crosby; Bernard F Cole; Jan L Fisher; Jill C Uhlenhake; Diane Mellinger; Cathy Foster; Zbigniew M Szczepiorkowski; Susan M Webber; Alan R Schned; Robert D Harris; Richard J Barth; John A Heaney; Randolph J Noelle; Marc S Ernstoff
Journal:  Clin Cancer Res       Date:  2009-07-21       Impact factor: 12.531

8.  Injection by various routes of melanoma antigen-associated macrophages: biodistribution and clinical effects.

Authors:  Thierry Lesimple; Annick Moisan; André Carsin; Isabelle Ollivier; Mireille Mousseau; Bernard Meunier; Claudine Leberre; Brigitte Collet; Véronique Quillien; Bernard Drenou; Claudia Lefeuvre-Plesse; Jacqueline Chevrant-Breton; Louis Toujas
Journal:  Cancer Immunol Immunother       Date:  2003-04-11       Impact factor: 6.968

Review 9.  Intralymphatic immunotherapy.

Authors:  Gabriela Senti; Pål Johansen; Thomas M Kündig
Journal:  Curr Opin Allergy Clin Immunol       Date:  2009-12

10.  Intralymphatic injections as a new administration route for allergen-specific immunotherapy.

Authors:  Julia M Martínez-Gómez; Pål Johansen; Iris Erdmann; Gabriela Senti; Reto Crameri; Thomas M Kündig
Journal:  Int Arch Allergy Immunol       Date:  2009-04-02       Impact factor: 2.749

View more
  9 in total

1.  Formulation and Delivery Technologies for mRNA Vaccines.

Authors:  Chunxi Zeng; Chengxiang Zhang; Patrick G Walker; Yizhou Dong
Journal:  Curr Top Microbiol Immunol       Date:  2020-06-02       Impact factor: 4.291

2.  Spatially resolved microfluidic stimulation of lymphoid tissue ex vivo.

Authors:  Ashley E Ross; Maura C Belanger; Jacob F Woodroof; Rebecca R Pompano
Journal:  Analyst       Date:  2016-11-30       Impact factor: 4.616

Review 3.  Dendritic cells based immunotherapy.

Authors:  Na Shang; Matteo Figini; Junjie Shangguan; Bin Wang; Chong Sun; Liang Pan; Quanhong Ma; Zhuoli Zhang
Journal:  Am J Cancer Res       Date:  2017-10-01       Impact factor: 6.166

Review 4.  COVID-19 vaccines and nanomedicine.

Authors:  Robert S Shapiro
Journal:  Int J Dermatol       Date:  2021-06-05       Impact factor: 3.204

Review 5.  Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines?

Authors:  Sharan Bobbala; Sarah Hook
Journal:  Pharm Res       Date:  2016-07-05       Impact factor: 4.580

6.  Resident memory CD8+ T cells in regional lymph nodes mediate immunity to metastatic melanoma.

Authors:  Aleksey K Molodtsov; Nikhil Khatwani; Jennifer L Vella; Kathryn A Lewis; Yanding Zhao; Jichang Han; Delaney E Sullivan; Tyler G Searles; Nicholas K Preiss; Tamer B Shabaneh; Peisheng Zhang; Aaron R Hawkes; Brian T Malik; Fred W Kolling; Edward J Usherwood; Sandra L Wong; Joseph D Phillips; Keisuke Shirai; Christina V Angeles; Shaofeng Yan; Tyler J Curiel; Yina H Huang; Chao Cheng; Mary Jo Turk
Journal:  Immunity       Date:  2021-09-14       Impact factor: 43.474

Review 7.  Splice-correction strategies for treatment of X-linked agammaglobulinemia.

Authors:  Burcu Bestas; Janne J Turunen; K Emelie M Blomberg; Qing Wang; Robert Månsson; Samir El Andaloussi; Anna Berglöf; C I Edvard Smith
Journal:  Curr Allergy Asthma Rep       Date:  2015-03       Impact factor: 4.806

8.  Photochemically-Mediated Inflammation and Cross-Presentation of Mycobacterium bovis BCG Proteins Stimulates Strong CD4 and CD8 T-Cell Responses in Mice.

Authors:  Ying Waeckerle-Men; Zuzanna K Kotkowska; Géraldine Bono; Agathe Duda; Isabel Kolm; Eleni M Varypataki; Beat Amstutz; Michael Meuli; Anders Høgset; Thomas M Kündig; Cornelia Halin; Peter Sander; Pål Johansen
Journal:  Front Immunol       Date:  2022-01-31       Impact factor: 7.561

Review 9.  mRNA cancer vaccines: Advances, trends and challenges.

Authors:  Qing He; Hua Gao; Dejiang Tan; Heng Zhang; Jun-Zhi Wang
Journal:  Acta Pharm Sin B       Date:  2022-03-23       Impact factor: 14.903

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.